Citation Impact
Citing Papers
Modulation of immune cell reactivity with cis -binding Siglec agonists
2021 StandoutNobel
Progress and challenges towards targeted delivery of cancer therapeutics
2018 Standout
Pharmacologic Targeting of Hypoxia-Inducible Factors
2019 StandoutNobel
NF-κB in inflammation and renal diseases
2015
Satb1 regulates the effector program of encephalitogenic tissue Th17 cells in chronic inflammation
2019 StandoutNobel
Mitigating risk in academic preclinical drug discovery
2015
Engineering precision nanoparticles for drug delivery
2020 Standout
Induction of apoptosis in chronic myelogenous leukemia cells through nuclear entrapment of BCR–ABL tyrosine kinase
2001
Deletion of the Src Homology 3 Domain and C-terminal Proline-rich Sequences in Bcr-Abl Prevents Abl Interactor 2 Degradation and Spontaneous Cell Migration and Impairs Leukemogenesis
2001
Maintenance of the Hematopoietic Stem Cell Pool by CXCL12-CXCR4 Chemokine Signaling in Bone Marrow Stromal Cell Niches
2006 Standout
Antibody-drug conjugates for cancer therapy: The technological and regulatory challenges of developing drug-biologic hybrids
2015
mTOR Signaling in Growth Control and Disease
2012 Standout
NF-κB signaling in inflammation
2017 Standout
A view on drug resistance in cancer
2019 StandoutNature
The FGF family: biology, pathophysiology and therapy
2009 Standout
Privileged Diazepine Compounds and Their Emergence as Bromodomain Inhibitors
2014
A novel mammalian endoplasmic reticulum ubiquitin ligase homologous to the yeast Hrd1
2003 StandoutNobel
Oncogenic kinase signalling
2001 StandoutNature
Signal integration by JNK and p38 MAPK pathways in cancer development
2009 Standout
Activation of tyrosine kinases by mutation of the gatekeeper threonine
2008
Mutational analysis of the regulatory function of the c-Abl Src homology 3 domain
2001
Distinct stem cell myeloproliferative/T lymphoma syndromes induced by ZNF198-FGFR1 and BCR-FGFR1 fusion genes from 8p11 translocations
2004
WNT signalling pathways as therapeutic targets in cancer
2012 Standout
Cancer drug resistance: an evolving paradigm
2013 Standout
HIF-1 mediates metabolic responses to intratumoral hypoxia and oncogenic mutations
2013 StandoutNobel
Bcr–Abl variants: biological and clinical aspects
2002
From inflammaging to healthy aging by dietary lifestyle choices: is epigenetics the key to personalized nutrition?
2015
Chronic myeloid leukemia stem cells possess multiple unique features of resistance to BCR-ABL targeted therapies
2007
Self-hydrolyzing maleimides improve the stability and pharmacological properties of antibody-drug conjugates
2014
Mechanism of Activation of the RAF-ERK Signaling Pathway by Oncogenic Mutations of B-RAF
2004 Standout
Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor
2010
Overcoming the challenges in administering biopharmaceuticals: formulation and delivery strategies
2014
Cancer stem cells in solid tumours: accumulating evidence and unresolved questions
2008 Standout
Tyrosine phosphorylation of Grb2 by Bcr/Abl and epidermal growth factor receptor: a novel regulatory mechanism for tyrosine kinase signaling
2001
Identification of Bronchioalveolar Stem Cells in Normal Lung and Lung Cancer
2005 Standout
Targeting cancer with small molecule kinase inhibitors
2008 Standout
Loss of β-Catenin Impairs the Renewal of Normal and CML Stem Cells In Vivo
2007
Fibroblast growth factor signalling: from development to cancer
2010 Standout
PEGylation as a strategy for improving nanoparticle-based drug and gene delivery
2015 Standout
Neutrophil extracellular traps in immunity and disease
2017 Standout
mTOR: from growth signal integration to cancer, diabetes and ageing
2010 Standout
Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders
2005 Standout
Differential regulation of myeloid leukemias by the bone marrow microenvironment
2013
Tumour heterogeneity and cancer cell plasticity
2013 StandoutNature
Survival signaling mediated by c-Jun NH2-terminal kinase in transformed B lymphoblasts
2002
EGFR Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib
2005 Standout
Common pitfalls in preclinical cancer target validation
2017 StandoutNobel
Cooperation of BCR-ABL and AML1/MDS1/EVI1 in blocking myeloid differentiation and rapid induction of an acute myelogenous leukemia
2001
Mechanisms controlling pathogenesis and survival of leukemic stem cells
2004
Mechanisms of Autoinhibition and STI-571/Imatinib Resistance Revealed by Mutagenesis of BCR-ABL
2003
Strategies and challenges for the next generation of antibody–drug conjugates
2017 Standout
Emerging formats for next-generation antibody drug conjugates
2015
Impaired DNA Replication within Progenitor Cell Pools Promotes Leukemogenesis
2005
Paul Ehrlich's magic bullet concept: 100 years of progress
2008 Standout
The STATs of cancer — new molecular targets come of age
2004 Standout
JAK-STAT signaling activated by Abl oncogenes
2000
SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules
2017 Standout
Global, In Vivo, and Site-Specific Phosphorylation Dynamics in Signaling Networks
2006 Standout
Cytokine Signaling in 2002
2002 Standout
Revisiting STAT3 signalling in cancer: new and unexpected biological functions
2014 Standout
Structural Basis for the Autoinhibition of c-Abl Tyrosine Kinase
2003 Standout
Preparation of Well‐Defined Antibody–Drug Conjugates through Glycan Remodeling and Strain‐Promoted Azide–Alkyne Cycloadditions
2014
Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach?
2009 Standout
Neutrophil recruitment and function in health and inflammation
2013 Standout
Engineered Nanoparticles for Drug Delivery in Cancer Therapy
2014 Standout
Requirement for CD44 in homing and engraftment of BCR-ABL–expressing leukemic stem cells
2006
Ocular delivery of proteins and peptides: Challenges and novel formulation approaches
2018
Cancer stem cells: an evolving concept
2012
JunB Deficiency Leads to a Myeloproliferative Disorder Arising from Hematopoietic Stem Cells
2004
Cell Cycle Regulation by Oncogenic Tyrosine Kinases in Myeloid Neoplasias: From Molecular Redox Mechanisms to Health Implications
2008
HIF activation causes synthetic lethality between the VHL tumor suppressor and the EZH1 histone methyltransferase
2017 StandoutNobel
SKI-606, a 4-anilino-3-quinolinecarbonitrile dual inhibitor of Src and Abl kinases, is a potent antiproliferative agent against chronic myelogenous leukemia cells in culture and causes regression of K562 xenografts in nude mice.
2003
β-Arrestin2 mediates the initiation and progression of myeloid leukemia
2012 StandoutNobel
Introducing Glycolinkers for the Functionalization of Cytotoxic Drugs and Applications in Antibody–Drug Conjugation Chemistry
2016
Analysis of the Structural Diversity, Substitution Patterns, and Frequency of Nitrogen Heterocycles among U.S. FDA Approved Pharmaceuticals
2014 Standout
Principles of interleukin (IL)-6-type cytokine signalling and its regulation
2003 Standout
Cancers predispose neutrophils to release extracellular DNA traps that contribute to cancer-associated thrombosis
2012
Targeting multiple kinase pathways in leukemic progenitors and stem cells is essential for improved treatment of Ph + leukemia in mice
2006
An orally bioavailable parthenolide analog selectively eradicates acute myelogenous leukemia stem and progenitor cells
2007 Standout
Dietary and Policy Priorities for Cardiovascular Disease, Diabetes, and Obesity
2016 Standout
A new tubulin-binding site and pharmacophore for microtubule-destabilizing anticancer drugs
2014
Overriding Imatinib Resistance with a Novel ABL Kinase Inhibitor
2004 StandoutScience
Emerging understanding of the protein corona at the nano-bio interfaces
2016
Targeting chronic myeloid leukemia stem cells with the hypoxia-inducible factor inhibitor acriflavine
2017
Hepatocellular Carcinoma: Epidemiology and Molecular Carcinogenesis
2007 Standout
A murine model of CML blast crisis induced by cooperation between BCR/ABL and NUP98/HOXA9
2002
Heterocyclic Anticancer Compounds: Recent Advances and the Paradigm Shift towards the Use of Nanomedicine’s Tool Box
2015 Standout
The molecular biology of chronic myeloid leukemia
2000
ATM Mediates Cytotoxicity of a Mutant Telomerase RNA in Human Cancer Cells
2008 StandoutNobel
Clinical resistance to the kinase inhibitor STI-571 in chronic myeloid leukemia by mutation of Tyr-253 in the Abl kinase domain P-loop
2002
Leukemia stem cells in a genetically defined murine model of blast-crisis CML
2007
Systematic Screening and Therapeutic Evaluation of Glyconanoparticles with Differential Cancer Affinities for Targeted Cancer Therapy
2022
Socs-1 Inhibits TEL-JAK2-Mediated Transformation of Hematopoietic Cells through Inhibition of JAK2 Kinase Activity and Induction of Proteasome-Mediated Degradation
2001
Therapeutic antibodies that target inflammatory cytokines in autoimmune diseases
2015
Photothermal Nanomaterials: A Powerful Light-to-Heat Converter
2023 Standout
HIF1α is required for survival maintenance of chronic myeloid leukemia stem cells
2012
Works of Ryan P. Million being referenced
Monoclonal antibody biosimilars
2015
Impact of genetic diagnostics on drug development strategy
2006
The epigenetics pipeline
2013
Targeting the IL-17–TH17 pathway
2014
The Grb2 binding site is required for the induction of chronic myeloid leukemia-like disease in mice by the Bcr/Abl tyrosine kinase
2000
The Tel-Abl (ETV6-Abl) tyrosine kinase, product of complex (9;12) translocations in human leukemia, induces distinct myeloproliferative disease in mice
2002
Antibody–drug conjugates
2013
The P190, P210, and P230 Forms of the BCR/ABL Oncogene Induce a Similar Chronic Myeloid Leukemia–like Syndrome in Mice but Have Different Lymphoid Leukemogenic Activity
1999
The Grb2 binding site is required for the induction of chronic myeloid leukemia-like disease in mice by the Bcr/Abl tyrosine kinase
2000